Investment analysts at Wolfe Research began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) in a research note issued on Tuesday, MarketBeat reports. The brokerage set an "outperform" rating and a $20.00 price target on the stock. Wolfe Research's price objective points to a potential upside of 40.75% from the company's current price.
Several other research firms have also recently weighed in on ORKA. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, December 20th. Wedbush reiterated an "outperform" rating and set a $40.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Finally, Stifel Nicolaus began coverage on shares of Oruka Therapeutics in a research note on Friday, October 11th. They issued a "buy" rating and a $49.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $39.86.
Get Our Latest Analysis on ORKA
Oruka Therapeutics Trading Up 3.7 %
Shares of ORKA stock traded up $0.51 on Tuesday, reaching $14.21. 190,937 shares of the stock were exchanged, compared to its average volume of 296,174. The company has a market capitalization of $497.35 million, a PE ratio of -2.27 and a beta of 0.77. Oruka Therapeutics has a one year low of $10.95 and a one year high of $53.88. The firm's 50 day moving average price is $18.09.
Institutional Trading of Oruka Therapeutics
Institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company purchased a new stake in shares of Oruka Therapeutics during the third quarter valued at $1,037,000. FMR LLC acquired a new position in Oruka Therapeutics during the 3rd quarter valued at about $114,763,000. Great Point Partners LLC acquired a new position in shares of Oruka Therapeutics during the third quarter valued at about $12,614,000. Braidwell LP purchased a new position in shares of Oruka Therapeutics in the third quarter worth $12,640,000. Finally, Janus Henderson Group PLC purchased a new position in Oruka Therapeutics in the 3rd quarter worth $5,840,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
